Magnetic Resonance Imaging Criteria for Thrombolysis in Acute Cerebral Infarct
Open Access
- 1 February 2005
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 36 (2), 388-397
- https://doi.org/10.1161/01.str.0000152268.47919.be
Abstract
Background and Purpose— Magnetic resonance imaging (MRI) selection of stroke patients eligible for thrombolytic therapy is an emerging application. Although the efficacy of therapy within 3 hours after onset of symptoms with intravenous (IV) tissue plasminogen activator (tPA) has been proven for patients selected with computed tomography (CT), no randomized, double-blinded MRI trial has been published yet. Summary of Review— MRI screening of acute stroke patients before thrombolytic therapy is performed in some cerebrovascular centers. In contrast to the CT trials, MRI pilot studies demonstrate benefit of therapy up to 6 hours after onset of symptoms. This article reviews the literature that has lead to current controlled MRI-based thrombolysis trials. We examined the MRI criteria applied in 5 stroke centers. Along with the personal views of clinicians at these centers, the survey reveals a variety of clinical and MRI technical aspects that must be further investigated: the therapeutic consequence of microbleeds, the use of magnetic resonance angiography, dynamic time windows, and others. Conclusion— MRI is an established application in acute evaluation of stroke patients and may suit as a brain clock, replacing the currently used epidemiological time clock when deciding whether to initiate thrombolytic therapy. MRI criteria for thrombolytic therapy are applied in some cerebrovascular centers, but the results of ongoing clinical trials must be awaited before it is possible to reach consensus.Keywords
This publication has 44 references indexed in Scilit:
- Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trialsThe Lancet, 2004
- Baseline Magnetic Resonance Imaging Parameters and Stroke Outcome in Patients Treated by Intravenous Tissue Plasminogen ActivatorStroke, 2003
- Late secondary ischemic injury in patients receiving intraarterial thrombolysisAnnals of Neurology, 2002
- Diffusion‐ and perfusion‐weighted MRI response to thrombolysis in strokeAnnals of Neurology, 2001
- Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imagingAnnals of Neurology, 2000
- Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom OnsetJAMA, 1999
- Evaluation of early reperfusion and IV tPA therapy using diffusion- and perfusion-weighted MRINeurology, 1999
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)The Lancet, 1998
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric StrokeJAMA, 1995